Use of becaplermin in the closure of pharyngocutaneous fistulas

David M. Jakubowicz, Richard V. Smith

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background. We report on the contribution of recombinant platelet-derived growth factor-BB (becaplermin) in treating recalcitrant postlaryngectomy fistulas in two patients with head and neck cancer. Methods. Topical becaplermin was applied daily, with periodic wound assessment and photodocumentation. Results. The two patients with persistent fistula refractory to conventional management have demonstrated rapid improvement after topical application of becaplermin. Each wound exhibited an exuberant granulation response, with a 50% decrease in the size of wound at 1 week. The patients experienced eventual closure, with none having local recurrence of their cancer at 2 years' follow-up. Conclusions. Becaplermin seems to be a promising addition to traditional methods of treatment for postlaryngectomy fistulas. In patients with delayed healing, future studies will be required to determine the overall efficacy of such biologic response modifiers in the treatment of pharyngocutaneous fistulas and other chronic wounds of the head and neck.

Original languageEnglish (US)
Pages (from-to)433-438
Number of pages6
JournalHead and Neck
Volume27
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Fistula
Wounds and Injuries
Head and Neck Neoplasms
Neck
Head
platelet-derived growth factor BB
Recurrence
Therapeutics
Neoplasms

Keywords

  • Becaplermin
  • Complications
  • Laryngectomy, Regranex
  • Pharyngocutaneous fistula
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Use of becaplermin in the closure of pharyngocutaneous fistulas. / Jakubowicz, David M.; Smith, Richard V.

In: Head and Neck, Vol. 27, No. 5, 05.2005, p. 433-438.

Research output: Contribution to journalArticle

Jakubowicz, David M. ; Smith, Richard V. / Use of becaplermin in the closure of pharyngocutaneous fistulas. In: Head and Neck. 2005 ; Vol. 27, No. 5. pp. 433-438.
@article{8c848c3fe39648719297e382abe4cc2d,
title = "Use of becaplermin in the closure of pharyngocutaneous fistulas",
abstract = "Background. We report on the contribution of recombinant platelet-derived growth factor-BB (becaplermin) in treating recalcitrant postlaryngectomy fistulas in two patients with head and neck cancer. Methods. Topical becaplermin was applied daily, with periodic wound assessment and photodocumentation. Results. The two patients with persistent fistula refractory to conventional management have demonstrated rapid improvement after topical application of becaplermin. Each wound exhibited an exuberant granulation response, with a 50{\%} decrease in the size of wound at 1 week. The patients experienced eventual closure, with none having local recurrence of their cancer at 2 years' follow-up. Conclusions. Becaplermin seems to be a promising addition to traditional methods of treatment for postlaryngectomy fistulas. In patients with delayed healing, future studies will be required to determine the overall efficacy of such biologic response modifiers in the treatment of pharyngocutaneous fistulas and other chronic wounds of the head and neck.",
keywords = "Becaplermin, Complications, Laryngectomy, Regranex, Pharyngocutaneous fistula, Squamous cell carcinoma",
author = "Jakubowicz, {David M.} and Smith, {Richard V.}",
year = "2005",
month = "5",
doi = "10.1002/hed.20182",
language = "English (US)",
volume = "27",
pages = "433--438",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Use of becaplermin in the closure of pharyngocutaneous fistulas

AU - Jakubowicz, David M.

AU - Smith, Richard V.

PY - 2005/5

Y1 - 2005/5

N2 - Background. We report on the contribution of recombinant platelet-derived growth factor-BB (becaplermin) in treating recalcitrant postlaryngectomy fistulas in two patients with head and neck cancer. Methods. Topical becaplermin was applied daily, with periodic wound assessment and photodocumentation. Results. The two patients with persistent fistula refractory to conventional management have demonstrated rapid improvement after topical application of becaplermin. Each wound exhibited an exuberant granulation response, with a 50% decrease in the size of wound at 1 week. The patients experienced eventual closure, with none having local recurrence of their cancer at 2 years' follow-up. Conclusions. Becaplermin seems to be a promising addition to traditional methods of treatment for postlaryngectomy fistulas. In patients with delayed healing, future studies will be required to determine the overall efficacy of such biologic response modifiers in the treatment of pharyngocutaneous fistulas and other chronic wounds of the head and neck.

AB - Background. We report on the contribution of recombinant platelet-derived growth factor-BB (becaplermin) in treating recalcitrant postlaryngectomy fistulas in two patients with head and neck cancer. Methods. Topical becaplermin was applied daily, with periodic wound assessment and photodocumentation. Results. The two patients with persistent fistula refractory to conventional management have demonstrated rapid improvement after topical application of becaplermin. Each wound exhibited an exuberant granulation response, with a 50% decrease in the size of wound at 1 week. The patients experienced eventual closure, with none having local recurrence of their cancer at 2 years' follow-up. Conclusions. Becaplermin seems to be a promising addition to traditional methods of treatment for postlaryngectomy fistulas. In patients with delayed healing, future studies will be required to determine the overall efficacy of such biologic response modifiers in the treatment of pharyngocutaneous fistulas and other chronic wounds of the head and neck.

KW - Becaplermin

KW - Complications

KW - Laryngectomy, Regranex

KW - Pharyngocutaneous fistula

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=17844374056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844374056&partnerID=8YFLogxK

U2 - 10.1002/hed.20182

DO - 10.1002/hed.20182

M3 - Article

C2 - 15776464

AN - SCOPUS:17844374056

VL - 27

SP - 433

EP - 438

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 5

ER -